The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III
Open accessAbstract
Objective: Amyotrophic lateral sclerosis (ALS) is a devastating, and currently incurable, neuromuscular disease in which oxidative stress and mitochondrial impairment are contributing to neuronal loss. Coenzyme Q10 (CoQ10), an antioxidant and mitochondrial cofactor, has shown promise in ALS transgenic mice, and in clinical trials for neurodegenerative diseases other than ALS. Our aims were to choose between two high doses of CoQ10 for ALS, and to determine if it merits testing in a Phase III clinical trial. Methods: We designed and implemented a multicenter trial with an adaptive, two‐stage, bias‐adjusted, randomized, placebo‐controlled, double‐blind, Phase II design (n = 185). The primary outcome in both stages was a decline in the ALS Functional Rating Scale‐revised (ALSFRSr) score over 9 months. Stage 1 (dose selection, 35 participants per group) compared CoQ10 doses of 1,800 and 2,700mg/day. Stage 2 (futility test, 75 patients per group) compared the dose selected in Stage 1 against placebo. Results: Stage 1 selected the 2,700mg dose. In Stage 2, the pre‐specified primary null hypothesis that this dose is superior to placebo was not rejected. It was rejected, however, in an accompanying prespecified sensitivity test, and further supplementary analyses. Prespecified secondary analyses showed no significant differences between CoQ10 at 2,700mg/day and placebo. There were no safety concerns. Interpretation: CoQ10 at 2,700mg daily for 9 months shows insufficient promise to warrant Phase III testing. Given this outcome, the adaptive Phase II design incorporating a dose selection and a futility test avoided the need for a much larger conventional Phase III trial. Ann Neurol 2009;66:235–244
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“SOD 1 is an enzyme that plays a role in detoxifying free radicals.(7) In a transgenic mouse model of familial ALS, there is increased oxidative stress.”
BackgroundEl Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · cited 1×
“Participants were aged 21 to 85 years with a clinical diagnosis of definite, probable, or laboratorysupported probable ALS, either sporadic or familial, by El Escorial guidelines.(29) Exclusion criteria were forced vital capacity (FVC) of less than 60%, severe medical illness, or disease onset more than 5 years before…”
MethodCedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 2×
“A study in Parkinson’s disease patients had found that doses up to 1,600mg daily were well tolerated.(22) In a pilot trial of 17 patients receiving escalating doses of CoQ10 (1,200mg, 1,800mg, 2,400mg, and 3,000mg daily) the plasma levels reached a plateau at the 2,400mg dose and did not increase further at the 3,000m…”
BackgroundMatthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557
Shults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326
Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease
Shults, C. W., Flint Beal, M., Song, D., & Fontaine, D. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.003 · Cited by 223
Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998
Sorenson, E. J., Stalker, A. P., Kurland, L. T., & Windebank, A. J. (2002) · Neurology · doi:10.1212/wnl.59.2.280 · Cited by 205
Kaufmann, P., Levy, G., Montes, J., Buchsbaum, R., Barsdorf, A. I., Battista, V., Arbing, R., Gordon, P. H., Mitsumoto, H., Levin, B., et al. (2007) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960600888156 · Cited by 145
Self-citationAn increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients
Sohmiya, M., Tanaka, M., Suzuki, Y., Tanino, Y., Okamoto, K., & Yamamoto, Y. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.09.030 · Cited by 69
Cited by
Oxidative Stress in Neurodegenerative Diseases
Simonian, N. A., & Coyle, J. T. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.000503 · Cited by 1,377
Oxidative Stress in Neurodegenerative Diseases
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9337-5 · Cited by 800
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
Philips, T., & Robberecht, W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70015-1 · Cited by 646
The role of mitochondria in amyotrophic lateral sclerosis
Smith, E. F., Shaw, P. J., & De Vos, K. J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2017.06.052 · Cited by 559
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00068 · Cited by 451
NADPH oxidase in brain injury and neurodegenerative disorders
Ma, M. W., Wang, J., Zhang, Q., Wang, R., Dhandapani, K. M., Vadlamudi, R. K., & Brann, D. W. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0150-7 · Cited by 432
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Flint Beal, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 413
Galasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.85 · Cited by 377
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis
D’Amico, E., Factor-Litvak, P., Santella, R. M., & Mitsumoto, H. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.029 · Cited by 321
Self-citationMitsumoto, H., Brooks, B. R., & Silani, V. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70129-2 · Cited by 289
Self-citationThe role of mitochondrial DNA mutations and free radicals in disease and ageing
Lagouge, M., & Larsson, N. ‐. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12055 · Cited by 266
Energy metabolism in ALS: an underappreciated opportunity?
Vandoorne, T., De Bock, K., & Van Den Bosch, L. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1835-x · Cited by 262
Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Cheah, B. C., Vucic, S., Krishnan, A., & Kiernan, M. C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791163939 · Cited by 258
Adaptive trial designs: a review of barriers and opportunities
Kairalla, J. A., Coffey, C. S., Thomann, M. A., & Muller, K. E. (2012) · Trials · doi:10.1186/1745-6215-13-145 · Cited by 249
Novel Methods and Technologies for 21st-Century Clinical Trials: A Review
Dorsey, E. R., Venuto, C., Venkataraman, V., Harris, D. A., & Kieburtz, K. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4524 · Cited by 118
Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis
Ilieva, H., Vullaganti, M., & Kwan, J. (2023) · BMJ · doi:10.1136/bmj-2023-075037 · Cited by 111
Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease
Orrell, R. W., Lane, R. J., & Ross, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002829.pub4 · Cited by 98
Coenzyme Q and Its Role in the Dietary Therapy against Aging
Varela-López, A., Giampieri, F., Battino, M., & Quiles, J. (2016) · Molecules · doi:10.3390/molecules21030373 · Cited by 86
Miller, R. G., Moore, D. H., Forshew, D. A., Katz, J. S., Barohn, R. J., Valan, M., Bromberg, M. B., Goslin, K. L., Graves, M. C., McCluskey, L. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822dc7a5 · Cited by 70
Self-citationSikorska, M., Lanthier, P., Miller, H., Beyers, M., Sodja, C., Zurakowski, B., Gangaraju, S., Pandey, S., & Sandhu, J. K. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.032 · Cited by 70
Metadata
- Authors
- Kaufmann, P., Thompson, J. L. P., Levy, G., Buchsbaum, R., Shefner, J., Krivickas, L. S., Katz, J., Rollins, Y., Barohn, R. J., Jackson, C. E., Tiryaki, E., Lomen‐Hoerth, C., Armon, C., Tandan, R., Rudnicki, S. A., Rezania, K., Sufit, R., Pestronk, A., Novella, S. P., Heiman‐Patterson, T., Kasarskis, E. J., Pioro, E. P., Montes, J., Arbing, R., Vecchio, D., Barsdorf, A., Mitsumoto, H., & Levin, B.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-08
- Volume
- 66
- Issue
- 2
- Pages
- 235-244
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2067106492
- Cited by
- 235
- References
- 10
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.